Apixaban for AF in ESRD: Fewer Strokes, Major Bleeds vs Warfarin

Share this post

‘I think this is the best data we have so far’ supporting the use of apixaban in the especially high-risk population with atrial fibrillation, the lead researcher concludes. A randomized trial is forthcoming.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply